Union Semiconductor Files for HKEX Listing, Ranked 2nd in China’s Advanced DDIC Packaging & Testing Sector
NewTimeSpace News: As disclosed by the Hong Kong Stock Exchange, Union Semiconductor (Hefei) Co., Ltd. filed for main board listing on May 29, 2026, with CICC appointed as the sole sponsor.
The company is a semiconductor packaging and testing service provider focusing on advanced packaging and testing solutions for DDIC. Its service portfolio is built around four core process technologies: bumping, wafer testing, glass flip chip and thin-film flip chip. In 2025, the company recorded revenue of RMB 1.783 billion, representing a year-on-year increase of 18.8%, with wafer shipments hitting 511.3 thousand pieces. It stands as the world’s fourth-largest provider of advanced DDIC packaging and testing services. Per Frost & Sullivan data, it ranked second by revenue in mainland China’s advanced DDIC packaging and testing market, and second by 12-inch wafer bump shipments across mainland China’s packaging and testing industry in 2025.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSPC Pharmaceutical Group (01093.HK): Albumin-Bound Docetaxel Combined with Anitumab Granted Breakthrough Therapy Designation
- China Everbright Water (01857.HK): Completes Issuance of Phase 1 Medium-Term Notes of 2026 with Principal of RMB 1.5 Billion
- MicroTech Medical(02235.HK): Continuous Glucose Monitoring System Secures Marketing Approval in South Korea
- Overseas Chinese Town Asia (03366.HK): 100% Equity Interest in Huizhou Project Put Up for Public Listing Sale, Winning Bid Price at Approximately RMB 307 Million
- Sino Biopharmaceutical (01177.HK): TRD205 (AT2R Antagonist) Included in CDE’s Breakthrough Therapy Designation List